5th International Conference on Immunotherapy in Pediatric Oncology (CIPO2020)

Conference Program

Thursday, Sept. 24, 2020

2:30 p.m. Sign-In
3:00 p.m. Welcome/Opening
Jeff Sperring, MD; CEO Seattle Children’s
(Introduced by Dr. Michael Jensen)  

Session I: Immunotherapy: A Shared Success, and a Future Challenge

3:10 p.m. Keynote: Where We Have Come From and Where We Are Going in Immunotherapy
Malcolm Brenner, MD, PhD, FRCP, FRCPath
4:05 p.m. Q & A  

Session II: Engineered T-Cell Approaches: Focus on CAR T
Moderator: Crystal Mackall, MD

4:15 p.m. Plenary: CD19-CART in Pediatric Pre-B ALL
Stephan Grupp, MD, PhD
4:40 p.m. Plenary: Advanced CAR-T Engineering Principles and Practice
Michael C. Jensen, MD
5:05 p.m. Plenary: CD19, CD20, CD33, and Beyond: New Frontiers in Hematologic Malignancies
Terry Fry, MD
5:45 p.m. Reception and Facility Tour  

Friday, Sept. 25, 2020

7:00 a.m. Continental Breakfast and Sign-In

Session II (cont.): Engineered T-Cell Approaches: Focus on CAR-T
Moderator: Terry Fry, MD

8:00 a.m. Plenary: Engineering T-Cell Metabolism and Function: New Approaches to Immunotherapy
Crystal Mackall, MD
8:25 a.m. Plenary: T Cells: Next Generation CAR T-cells to Target Solid Tumors
Stephen Gottschalk, MD
8:50 a.m. Short Talk – Early Career: CAR T for T-cell Lymphoma and ALL
Maksim Mamonkin, PhD
9:05 a.m. Short Talk – Early Career: Where Theory Meets Practice, CD22 CAR T in the Clinic
Nirali Shah, MD
9:20 a.m. Short Talk – Engineering CAR T Cells with Improved Efficacy in CNS Malignancies 
Meenakshi Hegde
9:35 a.m. Short Talk (Abstract Selection)
9:50 a.m. Break

Session III: Challenges Presented in the Tumor Microenvironment
Moderator: Poul Sorensen, MD, PhD

10:05 a.m. Plenary: The Pre-Metastatic Tumor Niche Sets the Stage for Immune Evasion
Rosandra Kaplan, MD
10:30 a.m. Plenary: Cancer and Immunometabolism
Russell Jones, PhD
10:55 a.m. Plenary: Novel Tumor: Immune Cell Interactions in Neuroblastoma and Glioma
Shahab Asgharzadeh, MD
11:20 a.m. Plenary: Brain Tumor Immunotherapy
Duane Mitchell, MD, PhD
11:55 a.m. Short Talk (Abstract Selection)
12:10 p.m. Lunch  

Session IV: Non T-Cell Based Immunotherapy Approaches
Moderator: Stephen Gottschalk, MD

1:30 p.m. Plenary: NK-CARs -CD19 and Beyond
Katy Rezvani, MD, PhD
1:55 p.m. Plenary: NKT Cells: A Novel Immunotherapeutic Platform for Pediatric Tumors
Leonid Metelitsa, MD, PhD
2:20 p.m. Plenary: “Smart” Synthetic Materials for In Vivo Immune Activation
Matthias Stephan, MD, PhD
2:45 p.m. Plenary: Engineering Macrophages to Reverse Tumor Lesion-Associated Immunosuppression
Courtney Crane, PhD
3:05 p.m. Short Talk (Abstract Selection)
3:20 p.m. Short Talk (Abstract Selection)  

Session V: Immunotherapy in the Context of HSCT and TCR Approaches
Moderator: Catherine Bollard, MD, MBChB

3:45 p.m. Plenary: Bone Marrow Transplant and Viral-Specific T Cells: The Roots of Immunotherapy
Catherine Bollard, MD, MBChB
4:10 p.m. Plenary: Engineered T Cells Expressing Recombinant TCRs for the Immunotherapy of Leukemia
Marie Bleakley, MD, PhD, M.MSC
4:35 p.m. Plenary: HSCT Graft Engineering as a Platform for Adoptive Immunotherapy
Rupert Handgretinger, MD
5:00 p.m. Short Talk (Abstract Selection)
5:15 p.m. Short Talk (Abstract Selection)
5:30-8:00 p.m. Poster Session and Reception

Saturday, Sept. 26, 2020

7:15 a.m. Continental Breakfast and Sign-In Poster Session

Session VI: Antibody-based Immunotherapy Approaches
Moderator: Paul Sondel, MD, PhD

8:00 a.m. Plenary: Antibody-Based Therapy for Neuroblastoma and Other Solid Tumors of Childhood
Nai-Kong Cheung, MD, PhD
8:25 a.m. Plenary: Bi-Specific and Multi-Specific Antibodies to Target Leukemia
Max Topp, MD
8:50 a.m. Plenary: Using Tumor Reactive mAb to Help Engage Innate and Adaptive Anti-tumor Immunity
Paul Sondel, MD, PhD
9:15 a.m. Short Talk – Early Career: Development of GPC2 ADCs for neuroblastoma and other cancers
Kristopher Bosse, MD
9:30 a.m. Short Talk – Early Career: Enhancing GD2 Based Immunotherapy for Neuroblastoma and Osteosarcoma  
Robbie Majzner, MD
9:45 a.m. Short Talk (Abstract Selection)
10:00 a.m. Break 

Session VII: Views from Patients, Industry, and Regulators to Advance Immunotherapy
Moderator: Crystal Mackall, MD

10:15 a.m. NCI’s Efforts to Accelerate Research in Childhood Cancer
Ned Sharpless, MD
10:45 a.m. Industry Views
Samuel Blackman, MD, PhD
11:15 a.m. Advocating for Patients
Nancy Goodman, JD
12:00 p.m. Lunch (provided onsite)

Session VIII: New Technologies and Targets
Moderator: Javed Khan, MD

1:00 p.m. Plenary: Targeting Peptides from Lineage Restricted Oncoprotein Presented on MHC in Pediatric Cancers
John Maris, MD
1:25 p.m. Plenary: Discovery Platforms for Antibody-Based Therapy of Pediatric Cancer
Poul Sorensen, MD, PhD, FRCPC
1:50 p.m. Plenary: Gene Editing and Circuit Discovery to Optimize Immune Effectors
Alexander Marson, MD, PhD
2:15 p.m. Plenary: Immuno-Transcriptomic Profiling To Identify Actionable Alterations in Pediatric Solid Malignancies
Javed Khan, MD
2:40 p.m. Plenary: Innovation in Target Discovery for Pediatric Cancer
Mads Daugaard, PhD
3:05 p.m. Coffee Break
3:20 p.m. Plenary: Molecular Drivers of Resistance and Susceptibility of Pediatric Tumors to Therapy
Uri Tabori, MD
3:45 p.m. Short Talk – Early Career: CAR-T Therapy for Glioblastoma
Giedre Krenciute, PhD
4:00 p.m. Short Talk – Early Career: Engineered Cell Products to Boost CAR-T Activity In Vivo
Colleen Annesley, MD

Session IX: Lessons from Tumor Biology Leading to Immunotherapeutic Advances

4:15 p.m. Keynote: Tumor Lesion Biology: Breaking Down Barriers to Successful Immunotherapy
Thomas Gajewski, MD, PhD
5:05 p.m. Q&A
5:15 p.m. Closing: Moving Therapy Forward
Patrick Sullivan, MD
5:45 p.m. Thank You & Closing
Rimas Orentas, PhD; Michael C. Jensen, MD